natgillin/translations-raw huggingface dataset:
For the full list of all side effects and restrictions with Adenuric, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Adenuric glejte navodilo za uporabo.
The most commonly reported side effects with Adenuric are gout flare-ups, abnormal liver test results, diarrhoea, nausea (feeling sick), headache, rash and oedema (swelling).
Najpogostejši neželeni učinki, o katerih so poročali pri uporabi zdravila Adenuric, so ponovni izbruhi protina, nenormalni izvidi jetrnih testov, driska, navzeja (slabost), glavobol, izpuščaji in edem (oteklina).
Adenuric is used in patients who already have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones', larger deposits of urate crystals that can cause joint and bone damage).
Zdravilo Adenuric se uporablja pri bolnikih, ki že kažejo znake odlaganja kristalov, vključno s protinskim artritisom (bolečino in vnetjem v sklepih) ali tofi („kamni“večjimi skupki kristalov urata, ki lahko povzročijo poškodbe sklepov in kosti).
What is the risk associated with Adenuric?
Kakšna tveganja so povezana z zdravilom Adenuric?
By reducing the production of uric acid, Adenuric can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up.
Z zmanjševanjem tvorbe sečne kisline lahko zdravilo Adenuric zniža njeno koncentracijo v krvi in jo vzdržuje na nizki ravni ter tako ustavi kopičenje kristalov.
Adenuric is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are on chemotherapy and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys).
Zdravilo Adenuric se uporablja tudi za zdravljenje in preprečevanje visokih ravni sečne kisline v krvi pri odraslih s krvnim rakom, ki prejemajo kemoterapijo in so izpostavljeni tveganju za sindrom tumorske lize (zapletu zaradi razgradnje rakavih celic, ki povzroči skokovito povečanje sečne kisline v krvi, kar lahko privede do okvare ledvic).
The first study, carried out in 1,072 patients, compared three doses of Adenuric (80, 120 and 240 mg once a day) with placebo (a dummy treatment) and allopurinol (another medicine used to treat hyperuricaemia).
V prvi študiji, izvedeni s 1 072 bolniki, so tri odmerke zdravila Adenuric (80, 120 in 240 mg enkrat na dan) primerjali s placebom (zdravilom brez zdravilne učinkovine) in alopurinolom (drugim zdravilom za zdravljenje hiperurikemije).
In the first study, 48% of the patients taking 80 mg Adenuric once a day (126 out of 262) and 65% of the patients taking 120 mg once a day (175 out of 269) had levels of uric acid below 6 mg/dl in the final three measurements.
V prvi študiji je imelo 48 % bolnikov (126 bolnikov od 262), ki so prejemali 80 mg zdravila Adenuric enkrat na dan, ter 65 % bolnikov (175 bolnikov od 269), ki so prejemali 120 mg enkrat na dan, pri zadnjih treh meritvah koncentracijo sečne kisline v krvi pod 6 mg/dl.
The CHMP concluded that Adenuric was more effective than allopurinol at lowering blood uric acid levels including in patients undergoing chemotherapy , but that it could carry a greater risk of side effects affecting the heart and blood vessels.
CHMP je zaključil, da je zdravilo Adenuric pri zniževanju koncentracije sečne kisline v krvi učinkovitejše od alopurinola, vključno pri bolnikih, ki prejemajo kemoterapijo, vendar pa lahko pomeni večje tveganje za neželene učinke, ki prizadenejo srce in ožilje.
Adenuric is used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate' in the blood).
Zdravilo Adenuric se uporablja za zdravljenje odraslih z dolgotrajno hiperurikemijo (visokimi koncentracijami sečne kisline ali urata v krvi).
The active substance in Adenuric, febuxostat, reduces the formation of uric acid.
Zdravilna učinkovina zdravila Adenuric, feboksustat, zmanjša tvorjenje sečne kisline.
This was compared with 22% of the patients taking allopurinol (60 out of 268) and none of the 134 patients taking placebo.
V skupini, ki je prejemala alopurinol je bilo takih bolnikov 22 % (60 bolnikov od 268), v skupini, ki je prejemala placebo, pa nobeden izmed 134 bolnikov.
The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/dl.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so bile ravni sečne kisline pri zadnjih treh meritvah nižje od 6 mg/dl. Koncentracijo sečne kisline v krvi so merili vsak mesec.
Why has Adenuric been approved?
Zakaj je bilo zdravilo Adenuric odobreno?
Rare serious hypersensitivity (allergic) reactions to Adenuric have occurred post-marketing.
Odkar je zdravilo na trgu, so bile resne preobčutljivostne (alergijske) reakcije na zdravilo Adenuric redke.
Adenuric was more effective than allopurinol and placebo in treating hyperuricaemia by reducing blood uric acid levels.
Zdravilo Adenuric je bilo pri zdravljenju hiperurikemije z zniževanjem koncentracije sečne kisline v krvi učinkovitejše od alopurinola in placeba.
Adenuric treatment should not be stopped if an attack of gout occurs.
V primeru zagona protina se zdravljenje z zdravilom Adenuric ne sme prekiniti.
This usually reduces blood uric acid levels within two weeks, but the dose can be increased to 120
To običajno zniža koncentracijo sečne kisline v krvi v dveh tednih, vendar pa je mogoče v primeru, če ostane koncentracija sečne kisline v krvi po dveh do štirih tednih visoka (nad 6 mg na
The second study compared two doses of Adenuric (80 and 120 mg once a day) with allopurinol over one year in 762 patients.
V drugi študiji so v obdobju enega leta pri 762 bolnikih primerjali dva odmerka zdravila Adenuric (80 in 120 mg enkrat na dan) z alopurinolom.
What is Adenuric used for?
Za kaj se zdravilo Adenuric uporablja?
What is Adenuric?
Kaj je zdravilo Adenuric?
How has Adenuric been studied?
Kako je bilo zdravilo Adenuric raziskano?
How does Adenuric work?
Kako zdravilo Adenuric deluje?
How is Adenuric used?
Kako se zdravilo Adenuric uporablja?
It may harm them,
Na podganah,
Make sure you do the following:
Poskrbite za naslednje:
This medicine could seriously harm your baby.
To zdravilo lahko hudo poškoduje otroka.
Do not change your daily dose without first talking to your doctor.
Dnevnih odmerkov ne spreminjajte, ne da bi se o tem najprej posvetovali s svojim zdravnikom.
Mild arthropathies are generally transient.
Blage artropatije so na splošno prehodne.
Ask your doctor which method is best for you.
Pri svojem zdravniku se pozanimajte, katera metoda je najboljša za vas.
It is very important for you to keep all of these appointments.
Zelo pomembno je, da redno opravite vse te teste.
Date of latest renewal: 21 September 2009
Datum zadnjega podaljšanja dovoljenje za promet: 21. september 2009
There are no adequate data from the use of deferiprone in pregnant women.
Ni zadostnih podatkov o uporabi deferiprona pri nosečnicah.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta.
Less severe episodes of neutropenia were reported in approximately 5% of patients.
Manj hude epizode nevtropenije so bile opažene pri približno 5 % pacientov.
In some patients it may be beneficial to reduce the dose of deferiprone and then scale it back up to the former dose.
Pri nekaterih bolnikih je koristno zmanjšati odmerek deferiprona in ga nato zopet zvišati na predhodni odmerek.
Combined use with other iron chelators
Sočasna uporaba z drugimi kelatorji železa
Therefore, in the event of neutropenia, rechallenge is not recommended.
Zato se v primeru nevtropenije ponovna uporaba ne priporoča.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 August 1999
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum odobritve: 25. avgust 1999
The neutrophil count should be then monitored more frequently.
Število nevtrofilcev je treba nato spremljati pogosteje.
• Whenever the risk management system is modified, especially as a result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
The Patient/Carer reminder card shall contain the following key messages:
Opozorilna kartica za bolnika/skrbnika mora vsebovati naslednja ključna sporočila:
The elimination half-life in most patients is 2 to 3 hours.
Pri večini bolnikov je razpolovna doba izločanja 2 do 3 ure.
− if you are HIV positive or if your liver or kidney function is severely impaired, your doctor may recommend additional tests.
− Če ste HIV pozitivni ali če je delovanje vaših jeter ali ledvic hudo okvarjeno, vam bo zdravnik morda priporočil dodatne preiskave.
((Inside 2))
((2. notranja stran))
The patient should be advised to limit contact with other individuals in order to reduce the risk of infection.
Bolniku svetujte, naj omeji stike z ljudmi in tako zmanjša tveganje za okužbo.
Non-clinical studies have been conducted in animal species including mice, rats, rabbits, dogs and monkeys.
Neklinične študije so bile izvedene na živalih, in sicer na miših, podganah, kuncih, psih in opicah.
• To warn women of childbearing age to not become pregnant because deferiprone may seriously harm the unborn baby.
• opozorilo za ženske v rodni dobi, da ne smejo zanositi, saj lahko deferipron resno škoduje nerojenemu otroku.
Suggested management of cases of neutropenia is outlined below.
Predlagan postopek obravnave primerov nevtropenije je opisan spodaj.
Monitoring of plasma Zn2+ concentration, and supplementation in case of a deficiency, is recommended.
Priporočljivo je spremljanje plazemske koncentracije Zn2+ in tudi dopolnjevanje v primeru pomanjkanja.
There are limited data available on the use of deferiprone in children between 6 and 10 years of age, and no data on deferiprone use in children under 6 years of age.
Podatki o uporabi deferiprona pri otrocih med 6 in 10 leti so omejeni, pri otrocih, mlajših od 6 let, pa podatkov o uporabi deferiprona ni.
− if you are allergic to deferiprone or any of the other ingredients of this medicine (listed in section 6).
− če ste alergični na deferipron ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
The total daily dose should not exceed 100 mg/kg.
Skupni dnevni odmerek ne sme preseči 100 mg/kg.
Plasma Zn2+ concentration
Plazemske koncentracije Zn2+
Systemic exposure to the inactive 3-O-glucuronide increased with decreasing eGFR.
Sistemska izpostavljenost neaktivnemu 3-Oglukuronidu je naraščala z zmanjševanjem eGFR.
Your doctor will also ask you to come in for tests to monitor body iron load.
Zdravnik vas bo tudi napotil na preiskave, s katerimi bo nadzoroval obremenitev telesa z železom.
If you miss more than one dose do not take a double dose to make up for forgotten individual doses, just continue with your normal schedule.
Če izpustite več kot en odmerek, ne vzemite dvojnega odmerka, da bi nadomestili pozabljene odmerke, ampak nadaljujte po običajnem razporedu.
FREQUENCY NOT KNOWN
NEZNANA POGOSTOST
The product information of deferoxamine should be consulted.
Preučiti je treba informacije o deferoksaminu.
A low white blood cell count can be associated with a serious and potentially life-threatening infection.
Nizko število belih krvnih celic je lahko povezano s hudo in potencialno življenjsko ogrožajočo okužbo.
− increase in appetite
- povečanje apetita
In case of overdose, close clinical supervision of the patient is required.
V primeru prevelikega odmerjanja je potreben skrben klinični nadzor bolnika.
No cases of acute overdose have been reported.
Ni poročil o primerih akutnega prevelikega odmerjanja.
complete, read the card carefully and carry it with you.
Kartico odstranite, izpolnite, natančno preberite in nosite s sabo.
- History of recurrent episodes of neutropenia.
- Anamneza ponavljajočih se epizod nevtropenije
For agranulocytosis (ANC < 0.5x109/l):
Za agranulocitozo (ANC < 0,5x109/l)
Data from pooled clinical studies in patients with systemic iron overload show that 63% of the episodes of agranulocytosis occurred within the first six months of treatment, 74% within the first year and 26% after one year of therapy.
Združeni podatki iz kliničnih študij, pridobljeni pri bolnikih s sistemsko preobremenitvijo z železom kažejo, da se je 63 % primerov agranulocitoze pojavilo v prvih šestih mesecih zdravljenja, 74 % v prvem letu in 26 % po enem letu zdravljenja.
Adverse reaction frequencies: Very common (≥1/10), Common (≥1/100 to <1/10), not known (cannot be estimated from the available data).
Tabelarični pregled neželenih učinkov Pogostost neželenih učinkov: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The response to therapy should be assessed periodically, and the occurrence of adverse events closely monitored.
Odziv bolnika na zdravljenje je treba periodično ocenjevati in pozorno spremljati pojav neželenih učinkov.
Sucralose (E955)
sukraloza (E955)
Use the measuring cup to measure the volume prescribed by your doctor.
Z merilno posodico izmerite količino, ki vam jo je predpisal zdravnik.
Even though agranulocytosis only affects 1 to 2 out of 100 users, it is important to monitor your blood on a regular basis.
Čeprav se agranulocitoza pojavi le pri 1 do 2 od 100 bolnikov, je zelo pomembno, da redno opravljate krvne teste.
− if you are pregnant or breast-feeding.
− če ste noseči ali dojite.
The median time to onset of the first episode of agranulocytosis was 190 days (ranged 22 days- 17.6 years) and median duration was 10 days in clinical trials.
Mediana časa do pojava prve epizode agranulocitoze je bila 190 dni (v razponu od 22 dni do 17,6 let), mediana trajanja v kliničnih preskušanjih pa je bila 10 dni.
There was an improvement in cardiac T2* of more than 3 ms in patients treated with Ferriprox compared with a change of about 1 ms in patients treated with deferoxamine.
Prišlo je do izboljšanja v srčnem T2* za več kot 3 ms pri pacientih, ki so jih zdravili z zdravilom Ferriprox v primerjavi s spremembo približno 1 ms pri pacientih, ki so jih zdravili z deferoksaminom.
It is not known whether deferiprone is excreted in human milk.
Ni znano, ali se deferipron izloča v materino mleko.
Dose adjustments should be tailored to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden).
Odmerek naj se prilagodi odzivu posameznika in terapevtskim ciljem (vzdrževanje ali zmanjševanje prekomerne količine železa v telesu).
In most cases, the pain disappeared while patients continued taking Ferriprox.
V večini primerov so bolečine izginile, medtem ko so bolniki nadaljevali z jemanjem zdravila Ferriprox.
((Inside 1))
((1. notranja stran))
FOR WOMEN OF CHILD BEARING AGE
((zadnja stran)) ZA ŽENSKE V RODNI DOBI
In the event of agranulocytosis, rechallenge is contraindicated.
V primeru agranulocitoze je ponovna uporaba kontraindicirana.
Increased levels of serum liver enzymes have been reported in some patients taking deferiprone.
Povečana količina serumskih encimov v jetrih je bila opažena pri nekaterih pacientih, ki jemljejo deferipron.
Some patients experienced progression of fibrosis associated with an increase in iron overload or hepatitis C.
Pri nekaterih bolnikih je prišlo do napredovanja fibroze, povezane s povečanjem obremenitve z železom ali s hepatitisom C.
The use of combination therapy should be considered on a case-by-case basis.
Za sočasno zdravljenje se je treba odločati na podlagi vsakega posameznega primera.
Cardiac endpoints were assessed by echocardiogram, electrocardiogram, the New York Heart Association classification and death due to cardiac disease.
Srčne mejne vrednosti so določili z ehokardiogramom, elektrokardiogramom in po klasifikaciji organizacije New York Heart Association ter smrti zaradi srčne bolezni.
This metabolite lacks iron-binding capability due to inactivation of the 3-hydroxy group of deferiprone.
Ta presnovek nima sposobnosti vezave železa zaradi inaktivacije 3-hidroksilne skupine deferiprona.
Gastrointestinal effects are more frequent at the beginning of therapy and resolve in most patients within a few weeks without the discontinuation of treatment.
Učinki na prebavila so pogostejši na začetku zdravljenja z deferipronom in v večini primerov izzvenijo v nekaj tednih, ne da bi prekinili zdravljenje.
A total daily dose above 100 mg/kg body weight is not recommended because of the potentially increased risk of adverse reactions (see sections 4.4, 4.8, and 4.9).
Skupni dnevni odmerek nad 100 mg/kg telesne mase ni priporočen zaradi možnega zvečanega tveganja za neželene učinke (glejte poglavja 4.4, 4.8 in 4.9).
Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia.
Zdravljenje z deferipronom naj uvede in nadzira zdravnik, ki ima izkušnje z zdravljenjem bolnikov s talasemijo.
Ferriprox will be most effective if you do not miss any doses.
Zdravilo Ferriprox bo najbolj učinkovito, če ne boste pozabili vzeti niti enega odmerka.
Important Safety Reminders for Patients taking Ferriprox (deferiprone) Prescribing doctor: _________________ Phone No: ________________________
Pomembna opozorila glede varnosti bolnikov, ki jemljejo zdravilo Ferriprox (deferipron) Zdravnik, ki je predpisal zdravilo:________________________
Neurological disorders have been observed in children treated with more than 2.5 times the maximum recommended dose for several years but have also been observed with standard doses of deferiprone.
Nevrološke motnje so opazili pri otrocih, ki so jih nekaj let zdravili z več kot 2,5-kratnim najvišjim priporočenim odmerkom, opazili pa so jih tudi pri standardnih odmerkih deferiprona.
In clinical trials, weekly monitoring of the neutrophil count has been effective in identifying cases of neutropenia and agranulocytosis.
V kliničnih preskušanjih se je tedensko spremljanje števila nevtrofilcev izkazalo za učinkovito pri odkrivanju primerov nevtropenije in agranulocitoze.
The amount of Ferriprox that you take will depend on your weight.
Količina zdravila Ferriprox, ki ga boste jemali, je odvisna od vaše telesne mase.
Number of tablets (three times/day)
Število tablet (trikrat/dan)
The safety of concurrent use of deferiprone and vitamin C has not been formally studied.
Varnost sočasne uporabe deferiprona in vitamina C ni preučena.
Evening
Zvečer
Evaluation of rate of reactions per 100 patient-years of exposure showed that only the rate of diarrhoea was significantly higher in children (11.1) than in adults (2.0, p=0.01).
Ocena stopnje reakcij na 100 bolnikov-let izpostavljenosti je pokazala, da je le stopnja driske bistveno višja pri otrocih (11,1) kot pri odraslih (2,0, p = 0,01).
If treatment is unavoidable, breast-feeding must be stopped (see section 4.3).
Če je zdravljenje neizogibno, je treba prenehati z dojenjem (glejte poglavje 4.3).
At the same time point, LVEF had increased from baseline by 3.07 ± 3.58 absolute units (%) in the Ferriprox group and by 0.32 ± 3.38 absolute units (%) in the deferoxamine group (difference between groups; p=0.003).
Hkrati se je LVEF povečal z osnovnega nivoja za 3,07 ± 3,58 absolutnih enot (%) v skupini, ki je jemala Ferriprox, in za 0,32 ± 3,38 absolutnih enot (%) v skupini, ki je jemala deferoksamin (razlika med skupinama; p = 0,003).
This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken Ferriprox in clinical studies.
Takšno stanje, znano kot tudi huda nevtropenija ali agranulocitoza, se je pojavilo pri 1 do 2 od 100 ljudi, ki so jemali zdravilo Ferriprox v kliničnih študijah.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Preobčutljivost za učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1
Regardless of the degree of renal impairment, the majority of the dose of Ferriprox was excreted in the urine over the first 24 hours as deferiprone 3-O-glucuronide.
Ne glede na stopnjo ledvične okvare je bil odmerek zdravila Ferriprox v večini izločen z urinom v prvih 24 urah v obliki deferipron-3-O-glukuronida.
If you do miss one dose take it as soon as you remember and take your next dose at its regularly scheduled time.
Če pozabite na odmerek, ga vzemite takrat, ko se na to spomnite, naslednji odmerek pa po običajnem razporedu.
The genotoxic potential of deferiprone was evaluated in a set of in vitro and in vivo tests.
Genotoksični potencial deferiprona je bil ocenjen v nizu preskusov in vitro ter in vivo.
5 years.
5 dni/teden).
An increase in MRI T2* on treatment indicates that iron is being removed from the heart.
Povečanje MRI T2* med zdravljenjem nakazuje, da se železo odstranjuje iz srca.
Women of childbearing potential must be advised to avoid pregnancy due to the clastogenic and teratogenic properties of the medicinal product.
Ženskam v rodni dobi je treba svetovati, naj ne zanosijo zaradi klastogenih in teratogenih lastnosti zdravila.
Deferiprone did not show direct mutagenic properties; however, it did display clastogenic characteristics in in vitro assays and in animals.
Pri deferipronu se niso pokazale neposredne mutagene lastnosti; pokazale pa so se klastogene lastnosti pri in vitro testih in pri živalih.
The active substance is deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a bidentate ligand which binds iron in a 3:1 molar ratio.
Učinkovina je deferipron (3-hidroksi-1,2-dimetilpiridin-4-on), bidentatni ligand, ki železo veže v molarnem razmerju 3:1.
In addition he or she might ask you to undergo liver biopsies.
Poleg tega vas bo morda napotil na biopsijo jeter.
If you have accidentally taken more than the prescribed dose, you should contact your doctor.
Če ste po nesreči vzeli večji odmerek od predpisanega, obvestite svojega zdravnika.
The change from weekly ANC monitoring to at the time of transfusion visits after 12 months of Ferriprox therapy, should be considered on an individual patient basis, according to the physician's assessment of the patient's understanding of the risk minimization measures required during therapy (see section 4.4 below).
Prehod s tedenskega spremljanja ANC na interval za transfuzijo po 12 mesecih zdravljenja z zdravilom Ferriprox je treba pretehtati za vsakega posameznega bolnika glede na zdravnikovo oceno bolnikovega razumevanja ukrepov za zmanjšanje tveganj, ki so potrebni med zdravljenjem (glejte poglavje 4.4 spodaj).
Doses of Ferriprox in those studies ranged from 50 to 100 mg/kg/day and doses of deferoxamine from 40 to 60 mg/kg/day.
Odmerki zdravila Ferriprox v teh študijah so se gibali v razponu od 50 do 100 mg/kg/dan in odmerki deferoksamina od 40 do 60 mg/kg/dan.
Prescribers are reminded that the use of doses above 100 mg/kg/day are not recommended.
Predpisovalci zdravila se morajo zavedati, da uporaba odmerkov, večjih od 100 mg/kg/dan, ni priporočljiva.
This may be extended to 2 hours in fed patients.
Ta čas se pri bolnikih, ki so že jedli, lahko podaljša na 2 uri.
These women should be advised to take contraceptive measures and must be advised to immediately stop taking deferiprone if they become pregnant or plan to become pregnant (see section 4.3).
Svetovati jim je treba uporabo ustrezne kontracepcije in takojšnje prenehanje uporabe deferiprona, če zanosijo ali načrtujejo zanositev (glejte poglavje 4.3).
• To increase patient awareness of the importance of regular monitoring of the neutrophil count during treatment with deferiprone
• za informiranje bolnikov o pomembnosti rednega spremljanja števila nevtrofilcev med zdravljenjem z deferipronom;